No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
FDA Fast Tracks Quince Therapeutics' Rare Ataxia Drug EryDex
Express News | FDA Grants Fast Track Designation To Quince Therapeutics' EryDex System To Treat Ataxia-Telangiectasia
Express News | Quince Therapeutics Receives U.S. FDA Fast Track Designation for Erydex System
Quince Therapeutics | 10-Q: Quarterly report
Express News | Quince Therapeutics - Expects Its Existing Cash Runway to Be Sufficient to Fund Company's Capital Efficient Development Plan Into 2026
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
Quince Therapeutics 1Q Loss/Shr 26c >QNCX
No Data